Impact of COVID-19 disease on clinical research in pediatric and congenital cardiology.

Congenital heart disease Drug trials Pandemic Randomized controlled trial SARS-CoV-2

Journal

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 13 09 2021
revised: 21 02 2022
accepted: 26 03 2022
pubmed: 7 5 2022
medline: 7 7 2022
entrez: 6 5 2022
Statut: ppublish

Résumé

COVID-19 triggered an unprecedented crisis affecting society at every level. Research in pediatric and congenital cardiology is currently in full development and may have been disrupted. The aim of the study was to determine the impact of COVID-19 on pediatric and congenital cardiology clinical research and to analyze decision-making and adaptation processes, from a panel of ongoing academic and industry-sponsored research at the time of the pandemic. This observational study was carried out in April 2020, from a CHD clinical research network involving five tertiary care pediatric and congenital cardiology centers. Investigators and clinical research assistants from each participating research center completed an online survey questionnaire, and each principal investigator underwent a 1-h web-based videoconference interview. A total of 34 study questionnaires were collected, reporting that 18 studies were totally suspended. Upon the investigator's decision, after discussion on ethical issues and with facilitating support from health authorities, 16 studies were resumed. The rate of study suspension in interventional research (53%) was similar to that in non-interventional research (56%). Logistical problems were predominantly reported in both continued and suspended trials. Research protocols were adapted, largely thanks to telemedicine, which in some cases even improved the course of the study. The impact of the COVID-19 pandemic on clinical research in pediatric and congenital cardiology has been limited by a rapid adaptation of all research structures and an extensive use of telemedicine at all stages of the studies.

Sections du résumé

BACKGROUND BACKGROUND
COVID-19 triggered an unprecedented crisis affecting society at every level. Research in pediatric and congenital cardiology is currently in full development and may have been disrupted. The aim of the study was to determine the impact of COVID-19 on pediatric and congenital cardiology clinical research and to analyze decision-making and adaptation processes, from a panel of ongoing academic and industry-sponsored research at the time of the pandemic.
METHODS METHODS
This observational study was carried out in April 2020, from a CHD clinical research network involving five tertiary care pediatric and congenital cardiology centers. Investigators and clinical research assistants from each participating research center completed an online survey questionnaire, and each principal investigator underwent a 1-h web-based videoconference interview.
RESULTS RESULTS
A total of 34 study questionnaires were collected, reporting that 18 studies were totally suspended. Upon the investigator's decision, after discussion on ethical issues and with facilitating support from health authorities, 16 studies were resumed. The rate of study suspension in interventional research (53%) was similar to that in non-interventional research (56%). Logistical problems were predominantly reported in both continued and suspended trials. Research protocols were adapted, largely thanks to telemedicine, which in some cases even improved the course of the study.
CONCLUSION CONCLUSIONS
The impact of the COVID-19 pandemic on clinical research in pediatric and congenital cardiology has been limited by a rapid adaptation of all research structures and an extensive use of telemedicine at all stages of the studies.

Identifiants

pubmed: 35523633
pii: S0929-693X(22)00106-3
doi: 10.1016/j.arcped.2022.03.004
pmc: PMC9020482
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

347-353

Informations de copyright

Copyright © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None

Références

Arch Latinoam Nutr. 2007 Dec;57(4):311-2
pubmed: 18524313
Telemed J E Health. 2020 May;26(5):571-573
pubmed: 32275485
Confl Health. 2018 May 14;12:23
pubmed: 29785204
Int J Cardiol. 2019 Aug 1;288:70-71
pubmed: 30879939
Lancet Haematol. 2020 Jan;7(1):e18-e27
pubmed: 31699660
Contemp Clin Trials Commun. 2019 Jun 08;15:100393
pubmed: 31249901
Lancet Haematol. 2019 Oct;6(10):e500-e509
pubmed: 31420317
Lancet. 2019 Mar 16;393(10176):1128-1137
pubmed: 30853151
Prog Pediatr Cardiol. 2019 Jun;53:1-10
pubmed: 31745384
Cardiol Young. 2015 Aug;25 Suppl 2:172-80
pubmed: 26377725
Patient Educ Couns. 2019 Dec;102(12):2223-2230
pubmed: 31262673
Eur J Cardiovasc Nurs. 2020 Aug;19(6):465-468
pubmed: 32418455
Ann Intern Med. 2007 Jun 19;146(12):878-81
pubmed: 17577007
ESC Heart Fail. 2020 Apr;7(2):747-756
pubmed: 32147955
Aten Primaria. 2020 Jun - Jul;52(6):418-422
pubmed: 32402477
J Cardiovasc Pharmacol. 2020 Jul;76(1):23-31
pubmed: 32168152
Eur J Phys Rehabil Med. 2020 Jun;56(3):327-330
pubmed: 32329593
Paediatr Drugs. 2020 Apr;22(2):123-147
pubmed: 31960361
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Circulation. 2019 Jan 2;139(1):51-63
pubmed: 30586694
Trials. 2017 Feb 7;18(1):61
pubmed: 28173843
Can J Diabetes. 2020 Jul;44(5):369
pubmed: 32405267
Int J Cardiol Heart Vasc. 2020 Mar 03;27:100489
pubmed: 32154361
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am Heart J. 2019 Nov;217:52-63
pubmed: 31493728
Am J Bioeth. 2020 Jul;20(7):37-43
pubmed: 32400291
Int J Cardiol. 2019 May 15;283:112-118
pubmed: 30616811

Auteurs

V Pommier (V)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Clinical Investigation Centre, University Hospital, Montpellier, France.

H Abassi (H)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Clinical Investigation Centre, University Hospital, Montpellier, France; PhyMedExp, CNRS, INSERM, University of Montpellier, Montpellier, France.

K Lavastre (K)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Clinical Investigation Centre, University Hospital, Montpellier, France.

J Calderon (J)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Clinical Investigation Centre, University Hospital, Montpellier, France; PhyMedExp, CNRS, INSERM, University of Montpellier, Montpellier, France; Cardiac Neurodevelopmental Program, Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States.

S Guillaumont (S)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Clinical Investigation Centre, University Hospital, Montpellier, France; Pediatric Cardiology and Rehabilitation Unit, St-Pierre Institute, Palavas-Les-Flots, France.

Y Dulac (Y)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Toulouse University Hospital, Toulouse CIC 1436, France.

F Auriol (F)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, Toulouse University Hospital, Toulouse CIC 1436, France.

C Ovaert (C)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, APHM La Timone University Hospital, Marseille, France.

A Blondelon (A)

Pediatric and Congenital Cardiology Department, M3C Regional Reference Centre, APHM La Timone University Hospital, Marseille, France.

S Hascoet (S)

Pediatric and Congenital Cardiology Department, M3C National Reference Centre, Centre Medico-Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France.

F Lecerf (F)

Pediatric and Congenital Cardiology Department, M3C National Reference Centre, Centre Medico-Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France.

C Jore (C)

Pediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Avenue de Magellan, Bordeaux 33604, France.

M Avesani (M)

Pediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Avenue de Magellan, Bordeaux 33604, France.

J-B Thambo (JB)

Pediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Avenue de Magellan, Bordeaux 33604, France; IHU Liryc, Electrophysiology and Heart Modelling Institute, INSERM 1045, Bordeaux University Foundation, Pessac, France.

P Amedro (P)

Pediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Avenue de Magellan, Bordeaux 33604, France; IHU Liryc, Electrophysiology and Heart Modelling Institute, INSERM 1045, Bordeaux University Foundation, Pessac, France. Electronic address: pascal.amedro@chu-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH